Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ensifentrine Dose 1 · 1 trial · 3 indications
Recovery = first day on which subject satisfies one of the following categories: not hospitalized, no limitations of activities; or not hospitalized, limitation of activities, home oxygen requirement, or both.
| Arm | Type | Description |
|---|---|---|
| Ensifentrine + Standard of Care | ACTIVE_COMPARATOR | 30 subjects randomized to receive blinded, inhaled ensifentrine in addition to standard of care treatment for COVID-19 infection |
| Placebo + Standard of Care | PLACEBO_COMPARATOR | 15 subjects randomized to receive blinded, inhaled placebo in addition to standard of care treatment for COVID-19 infection |
| Name | Type | Description |
|---|---|---|
| Ensifentrine Dose 1 | DRUG | Study drug delivered twice daily via pMDI |
| Placebo pMDI | DRUG | Placebo delivered twice daily via pMDI |
Inclusion Criteria: * Capable of giving informed consent indicating that they understand the purpose of the study and study procedures and agree to comply with the requirements and restrictions listed in the informed consent form and in this protocol. * Patient must be at least 18 years of age and ...
Ensifentrine Dose 1 is an investigational small molecule being studied for the treatment of Coronavirus Infection, including COVID-19 and SARS-CoV-2. It is delivered via a pressurized metered-dose inhaler (pMDI) and is intended for hospitalized patients with COVID-19. The drug is currently in Phase 2 clinical development.
Ensifentrine Dose 1 is being developed by Verona Pharma plc Sponsored ADR, which trades under the ticker symbol VRNA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with coronavirus infection.
Ensifentrine Dose 1 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial has been completed to assess its effects in hospitalized patients with COVID-19.
Ensifentrine Dose 1 has been studied in one completed Phase 2 clinical trial with the identifier NCT04527471. This trial was a randomized, double-blind, placebo-controlled pilot study that enrolled 45 participants in the United States. The study evaluated Ensifentrine or placebo delivered via pMDI in hospitalized patients with COVID-19.
Ensifentrine Dose 1 refers to a specific dose of the drug Ensifentrine. The clinical trial NCT04527471 investigated this dose in patients with COVID-19. Ensifentrine is a small molecule being developed by Verona Pharma for respiratory conditions, and this particular dose is being evaluated for coronavirus infection.